**INTRODUCTION**

Cancerperter (C-REV, formerly HIVI12) is an oncolytic, spontaneous mutant Herpes Simplex Virus type 1, and is one of the immunotherapies that combine direct tumor cell killing with immunomodulation. This study was designed to determine the recommended dose of C-REV in combination with gemcitabine (Gemcitabine + nab-paclitaxel) as first-line treatment of unresectable pancreatic cancer.

**MODE OF ACTIONS**

When locally injected into a tumor, C-REV shows two different effects as described below:

- Direct cytotoxic effects by viral replication.
- Tumor-selective antitumor activity by activated cytotoxic T-lymphocytes following tumor destruction.

**METHODS**

**Efficacy**

**Methods**

- **Dose Leveling Toxicity (DLT) (Dose escalation cohort)**
  - Written informed consent
  - Stage III or IV with unresectable pancreatic lesion
  - Injectable on EUS/ measurable pancreatic lesion
  - ECOG PS 0-1
  - Age ≤ 75 years
  - Total bilirubin level < 1.5xULN
  - Creatinine clearance ≥ 60 mL/min

- **Tumor marker**

- **Efficacy**

- **Survival**

- **Outcome**

- **Duration**

- **Conclusion**

**RESULTS**

**Summary of results**

- **Efficacy**

- **Survival**

- **Outcome**

- **Duration**

- **Conclusion**

**Corresponding author:** Yusuke Hashimoto, E-mail: yushashi@east.ncc.go.jp

**European Society for Medical Oncology 2019**

**ACKNOWLEDGEMENTS**

- Patients, their families and caregivers
- Dr. Yujiro Ohnishi (Nagoya University), originally established HT10
- TaKaRa Bio. Inc., funded this study

**CONCLUSIONS**

- The recommended dose was determined as 1x10^6 TCID50/mL, intratumoral C-REV serial injections are safe. The combination of C-REV and GnP suggested a favorable benefit/risk profile and encouraging antitumor activity in patients with unresectable pancreatic cancer.